NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DA-23-034 from the NIH Guide for Grants and Contracts
Notice NOT-OH-23-002 from the NIH Guide for Grants and Contracts
Notice NOT-GM-23-049 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-24-043 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Research and Entrepreneurial Development Immersion (REDI) Small Business Technology Transfer Research (STTR) Grant applications. The goal of this FOA is to foster the career development of early-career scientists with an interest in entrepreneurship by simultaneously supporting their entrepreneurial development and facilitating their transition to industry. This FOA utilizes the R41/R42 Industry Development Award to provide small business concerns (SBCs) the opportunity to support the hiring and salary of postdoctoral fellows and early-stage researchers as Principal Investigators/Program Directors (PIs/PDs) to increase their scientific research staff and support product development. Additionally, a major component of this FOA is a strong focus on entrepreneurial training, mentoring, and career development of the PD/PI. Postdoctoral fellows and early-career researchers with strong research skills and experience in technology discovery, and that have an interest in growing their entrepreneurial skillset and working in the industry, are optimal PD/PIs for this award. Given that the purpose of this FOA is to facilitate the PDs/PIs' transition to the SBC, most of their employment must be at the SBC.
Funding Opportunity RFA-HD-24-007 from the NIH Guide for Grants and Contracts. The goal of thisNOFO is to encourage research to understand the impact of ableism on health outcomes. Research on the underlying mechanisms by which ableism adversely influences the health of persons with disabilities (PWD), as well as developing and/or testing interventions at a community or health systems level to mitigate adverse health effects of ableism are high priority.
Notice NOT-AG-23-037 from the NIH Guide for Grants and Contracts
Notice NOT-DK-23-015 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-029 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections and complication and preventive strategies for HIV, as well as facilitating the translation of research findings into drug products that enables submission of an Investigational New Drug (IND) application to the FDA.
Notice NOT-HS-23-019 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-OH-24-002 from the NIH Guide for Grants and Contracts. NIOSH supports exploratory and developmental research projects (R21) that address issues related to diagnostic or treatment uncertainty with respect to individuals receiving monitoring and/or treatment under subtitle B of the James Zadroga 9/11 Health and Compensation Act of 2010 (Public Law 111347, as amended by Public Laws 114113, 11659 and 117-328). World Trade Center (WTC) responders, screening-eligible WTC survivors, and certified-eligible WTC survivors comprise the population targeted for the research project.
Funding Opportunity RFA-AG-24-041 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that investigate the neural and/or non-neural mechanisms that underlie the association between gait and cognition in aging and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Elucidating these mechanisms would help inform the potential use of changes gait as an early biomarker of AD/ADRD or inform the design of early interventions for AD/ADRD. To achieve these goals, it will be necessary to facilitate a team science approach by bringing experts together from various relevant disciplines, such as gerontology, neurology, neuropsychology, neurophysiology, neuroscience, neuroimaging, exercise physiology and physical therapy.
Funding Opportunity PAR-23-229 from the NIH Guide for Grants and Contracts. The Adolescent Brain Cognitive Development (ABCD) Study is the largest longitudinal study of brain development and child health collecting data from more than 11,000 children across the U.S. beginning when they are 9-10 years old and continuing for a decade. In addition to behavioral assessments, youth undergo neuroimaging and provide biospecimens, including saliva for hormone analysis, urine and hair for substance use and exposure, deciduous teeth for environmental exposure, and blood for genetic analysis and metabolic and hematologic assays. This initiative allows investigators to apply for access to biological samples from the ABCD Study. More information about the ABCD Study may be found on the ABCD Study website (www.abcdstudy.org). Information about this resource can be found on the NIDA funding opportunities page at https://nida.nih.gov/funding/nida-funding-opportunities/nih-brain-development-cohorts-biospecimen-access-program.
Funding Opportunity RFA-NS-24-007 from the NIH Guide for Grants and Contracts. This NOFO solicits applications for planning grants to assess feasibility and/or determine best practices to conduct community-engaged health equity research in neurological disorders with populations that experience health disparities (HDPs). If successful, these planning grants would support, enable and/or lay the groundwork for future clinical studies or trials.In addition to posing a research question related to addressing health disparities in neurological disorders, applicants must also be filling a gap in 1) Engagement with one or more HDP communities; and/or 2) Multidisciplinary research team expertise in neurological disorders, health disparities research and/or community-engaged research.Expected outcomes would advance understanding of drivers of health disparities and barriers to neurological health equity and establish collaborative research teams, including community partners, with appropriate expertise in community engagement with HDPs, health disparities research and neurological disorders.
Notice NOT-NS-23-106 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-162 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-24-021 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) seeks to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on Whole Person Health and enhancing pain treatment and management strategies towards personalized pain medicine. The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. Applicants are encouraged to develop and implement novel, multidisciplinary research approaches, and include investigators with complementary expertise to fulfill the project and program goals. Input from patients and caregivers on the goals of the project is highly encouraged. Rigorous data-driven and evidence-based research approaches supported under this NOFO are expected to provide better understanding of biological and/or biopsychosocial underpinnings of inter-individual differences, heterogeneity, and stratification of persons with lived pain experience, which would accelerate the development of evidence-based solutions toward precision pain medicine.
Funding Opportunity PAR-23-273 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) is intended to support mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including ones response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. NCI is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research.
Funding Opportunity RFA-NS-24-006 from the NIH Guide for Grants and Contracts. TBD
Funding Opportunity PAR-23-264 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy. The NOFO is intended to support discovery research for the identification of validated hits relevant to health-related outcomes of participating NIH Institutes. Stages of discovery research covered by this NOFO include: 1) assay development for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; 2) screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches to identify initial screening hits; 3) hit validation, including implementation of secondary assays that are orthogonal to the primary assay, advanced cheminformatics analysis and initial medicinal chemistry inspection to prioritize the hit set, and follow-up assays to characterize mode and mechanism of action of the validated hits; 4) hit-to-lead optimization, including SAR to optimize target engagement, selectivity and to minimize chemical liabilities, ADME, PK and PD studies, and, if appropriate, in vivo modeling to test efficacy or biological effects.
Notice NOT-DE-23-015 from the NIH Guide for Grants and Contracts